Vitamin China E-News 202109
Welcome to the September Issue of Vitamins China E-News.
This newsletter will help you stay ahead of the game in this fast-changing market with real-time reporting on the entire vitamin industry chain, from raw materials to end consumption. It includes breaking news from China and abroad, the latest market data (price, import & export, production, consumption, operating rates, etc.), in-depth analysis of market trends, and expert commentary from industry insiders.
Here is the Editor's Note for you to know about the September issue specifically:
In Sept., China's vitamin market was stable and buoyant. Since vitamin A, vitamin D3, and some other vitamin varieties had high transactions due to favorable factors, large producers increased their prices, lifting traders' prices and downstream inquiries. In this context, the vitamin market sentiment was boosted, leading to increased prices compared to a month earlier.
This year, the state has intensified the supervision on environmental protection, energy conservation and consumption reduction, with the ongoing 2nd-round central environmental protection inspection. Under the dual control of energy consumption policy released by many provinces, part intermediate ingredient producers face power and production limits, resulting in higher product prices. Downstream API industries, including the vitamin sector, will be affected inevitably, likely to push up their raw material costs.
As of 31 Aug., 15 domestic vitamin-related listed companies issued their performance report for H1 2021. Zhenhua Chemical ranked No.1 by the year-on-year growth of its revenue, while Yifan Pharmaceutical saw unsatisfactory revenue and net profit, down by 15.41% and 70.33% YoY respectively.
Four vitamin projects progressed this month, including the vitamin D3 production project of Donghui Bio-pharmaceutical, the 5,000 t/a vitamin D3, OME chlorides, and other pharmaceutical APIs & pharmaceutical intermediates production phase I project of Hongxuan Technology, the d-isoascorbic acid & sodium salt project of Tongliao Shengda Bio-Engineering, and the 1,000 t/a panthenol & 5,000 t/a nicotinamide project of Tiger Biotechnology.
On 3 Sept., the Ministry of Commerce and Industry of India announced that it has made an affirmative final anti-dumping ruling on vitamin C originating in or imported from China, with the imposition of 5-year anti-dumping duties to be recommended. Fortunately, China mainly exports the product to the US, Germany, and other developed countries, and thus the ruling will have a relatively small impact on the export.
The USD/RMB exchange rate in this Monthly Report is USD1.00=RMB6.4680 on 1 Sept, 2021, sourced from the People's Bank of China. All the prices mentioned in this Report will include the VAT, unless otherwise specified.
HEADLINE
This year, China has intensified the supervision on environmental protection, energy conservation and consumption reduction, with the ongoing 2nd-round central environmental protection inspection. On 11 Sept., the NDRC issued an official version Dual Control System Plan on Enhancing Total Energy Consumption and Energy Intensity.
As of 31 Aug., 15 vitamin-related listed companies in China published their performances for H1 2021, of which Zhenhua Chemical had satisfactory results while Yifan Pharmaceutical had depressed ones.
On 25 Aug., Brother Enterprises released its business performance report for H1 2021, with revenue up 34.52% YoY but net profit attributable to shareholders down 111.81% YoY.
Xianju Pharma announced that its holding subsidiary Hisound Pharmaceutical was ordered to suspend production and operation for rectification and got a fine due to safety problems.
On 28 Aug., Zhejiang SDM announced that its holding subsidiary, Tongliao Shengda Bio-Engineering, intends to construct a 20,000 t/a D-isoascorbic acid & sodium salt project.
Between 26 Aug. and 8 Sept., Hongxuan Technology publicised an EIA report of its 5,000 t/a pharmaceutical APIs & pharmaceutical intermediates production phase I project (including vitamin D3, OME chlorides, etc.).
On 3 Sept., Guangji Pharmaceutical announced that it proposes to sign a Product Cooperation Agreement with Sinopharm Group Hubei to carry out strategic cooperation on pharmaceutical APIs, pharmaceutical preparations, and pharmaceutical commercial distribution.
On 6 Sept., Tiger Biotechnology publicised an EIA report of its 1,000 t/a panthenol & 5,000 t/a nicotinamide project on the homepage of the Ecological and Environmental Bureau of Guzhen County, Bengbu City, Anhui Province.
On 3 Sept., the Ministry of Commerce and Industry of India announced that it has made an affirmative final antidumping ruling on vitamin C originating in or imported from China, with the imposition of 5-year anti-dumping duties to be recommended.
In Sept., the domestic vitamin market was stable and upward, with prices of vitamin A, vitamin D3, and some other vitamin varieties rising MoM due to the positive market condition and transactions.
This newsletter will help you stay ahead of the game in this fast-changing market with real-time reporting on the entire vitamin industry chain, from raw materials to end consumption. It includes breaking news from China and abroad, the latest market data (price, import & export, production, consumption, operating rates, etc.), in-depth analysis of market trends, and expert commentary from industry insiders.
Here is the Editor's Note for you to know about the September issue specifically:
In Sept., China's vitamin market was stable and buoyant. Since vitamin A, vitamin D3, and some other vitamin varieties had high transactions due to favorable factors, large producers increased their prices, lifting traders' prices and downstream inquiries. In this context, the vitamin market sentiment was boosted, leading to increased prices compared to a month earlier.
This year, the state has intensified the supervision on environmental protection, energy conservation and consumption reduction, with the ongoing 2nd-round central environmental protection inspection. Under the dual control of energy consumption policy released by many provinces, part intermediate ingredient producers face power and production limits, resulting in higher product prices. Downstream API industries, including the vitamin sector, will be affected inevitably, likely to push up their raw material costs.
As of 31 Aug., 15 domestic vitamin-related listed companies issued their performance report for H1 2021. Zhenhua Chemical ranked No.1 by the year-on-year growth of its revenue, while Yifan Pharmaceutical saw unsatisfactory revenue and net profit, down by 15.41% and 70.33% YoY respectively.
Four vitamin projects progressed this month, including the vitamin D3 production project of Donghui Bio-pharmaceutical, the 5,000 t/a vitamin D3, OME chlorides, and other pharmaceutical APIs & pharmaceutical intermediates production phase I project of Hongxuan Technology, the d-isoascorbic acid & sodium salt project of Tongliao Shengda Bio-Engineering, and the 1,000 t/a panthenol & 5,000 t/a nicotinamide project of Tiger Biotechnology.
On 3 Sept., the Ministry of Commerce and Industry of India announced that it has made an affirmative final anti-dumping ruling on vitamin C originating in or imported from China, with the imposition of 5-year anti-dumping duties to be recommended. Fortunately, China mainly exports the product to the US, Germany, and other developed countries, and thus the ruling will have a relatively small impact on the export.
The USD/RMB exchange rate in this Monthly Report is USD1.00=RMB6.4680 on 1 Sept, 2021, sourced from the People's Bank of China. All the prices mentioned in this Report will include the VAT, unless otherwise specified.
HEADLINE
This year, China has intensified the supervision on environmental protection, energy conservation and consumption reduction, with the ongoing 2nd-round central environmental protection inspection. On 11 Sept., the NDRC issued an official version Dual Control System Plan on Enhancing Total Energy Consumption and Energy Intensity.
As of 31 Aug., 15 vitamin-related listed companies in China published their performances for H1 2021, of which Zhenhua Chemical had satisfactory results while Yifan Pharmaceutical had depressed ones.
On 25 Aug., Brother Enterprises released its business performance report for H1 2021, with revenue up 34.52% YoY but net profit attributable to shareholders down 111.81% YoY.
Xianju Pharma announced that its holding subsidiary Hisound Pharmaceutical was ordered to suspend production and operation for rectification and got a fine due to safety problems.
On 28 Aug., Zhejiang SDM announced that its holding subsidiary, Tongliao Shengda Bio-Engineering, intends to construct a 20,000 t/a D-isoascorbic acid & sodium salt project.
Between 26 Aug. and 8 Sept., Hongxuan Technology publicised an EIA report of its 5,000 t/a pharmaceutical APIs & pharmaceutical intermediates production phase I project (including vitamin D3, OME chlorides, etc.).
On 3 Sept., Guangji Pharmaceutical announced that it proposes to sign a Product Cooperation Agreement with Sinopharm Group Hubei to carry out strategic cooperation on pharmaceutical APIs, pharmaceutical preparations, and pharmaceutical commercial distribution.
On 6 Sept., Tiger Biotechnology publicised an EIA report of its 1,000 t/a panthenol & 5,000 t/a nicotinamide project on the homepage of the Ecological and Environmental Bureau of Guzhen County, Bengbu City, Anhui Province.
On 3 Sept., the Ministry of Commerce and Industry of India announced that it has made an affirmative final antidumping ruling on vitamin C originating in or imported from China, with the imposition of 5-year anti-dumping duties to be recommended.
In Sept., the domestic vitamin market was stable and upward, with prices of vitamin A, vitamin D3, and some other vitamin varieties rising MoM due to the positive market condition and transactions.
Headline
Editor's Note
Column 1 Governmental Direction
China increases supervision on environmental protection, energy conservation and consumption
reduction
Column 2 Market Dynamics
15 vitamin listed firms release H1 2021 business results
Column 3 Company Developments
Brother Enterprises' revenue rises 34.52% YoY in H1 2021
Hisound Pharmaceutical suspended operation for rectification and fined
Zhejiang SDM's subsidiary proposes to build D-isoascorbic acid & sodium salt project
Hongxuan Technology's pharmaceutical APIs & intermediates production phase I project
Guangji Pharmaceutical proposes to cooperate with Sinopharm Group Hubei
Tiger Biotechnology publicises EIA for 1,000 t/a panthenol & 5,000 t/a nicotinamide project
Column 4 Import and Export Analysis
Imports and exports of selected vitamins in China, July 2021
India recommends 5-year anti-dumping duty on Chinese vitamin C imports
Column 5 Price Update
Ex-works prices of selected vitamins in China, Sept. 2021
Some vitamin varieties see buoyant transactions in Sept. 2021
Column 6 News in Brief
Progress of Shandong Tianli Pharm's 40,000 t/a VC-Na New & Old Energy Conversion Project
Donghui Bio-pharmaceutical publishes vitamin D3 production project EIA
Coenzyme Q10 residue application expanded to aquaculture animals
CFIA publishes 1st batch project initiation items of group standard for 2021
Guangji Pharm Mengzhou resumes production
Boxin Biotech proposes to build haematococcus pluvialis cultivation & astaxanthin extraction project
Garden Bio-Chem increases feed-grade vitamin D3 price
Xinling Chemical publicises EIA report of 5,100 t/a m-cresol upgrading project
Kunda Biotechnology suspends quotations and orders for niacinamide product
Hyperthermia and Vitamin C for Lung Cancer Treatment published in Journal of Advanced Research
Huaheng Biotech's biological enzyme-process ?-alanine derivatives project
Editor's Note
Column 1 Governmental Direction
China increases supervision on environmental protection, energy conservation and consumption
reduction
Column 2 Market Dynamics
15 vitamin listed firms release H1 2021 business results
Column 3 Company Developments
Brother Enterprises' revenue rises 34.52% YoY in H1 2021
Hisound Pharmaceutical suspended operation for rectification and fined
Zhejiang SDM's subsidiary proposes to build D-isoascorbic acid & sodium salt project
Hongxuan Technology's pharmaceutical APIs & intermediates production phase I project
Guangji Pharmaceutical proposes to cooperate with Sinopharm Group Hubei
Tiger Biotechnology publicises EIA for 1,000 t/a panthenol & 5,000 t/a nicotinamide project
Column 4 Import and Export Analysis
Imports and exports of selected vitamins in China, July 2021
India recommends 5-year anti-dumping duty on Chinese vitamin C imports
Column 5 Price Update
Ex-works prices of selected vitamins in China, Sept. 2021
Some vitamin varieties see buoyant transactions in Sept. 2021
Column 6 News in Brief
Progress of Shandong Tianli Pharm's 40,000 t/a VC-Na New & Old Energy Conversion Project
Donghui Bio-pharmaceutical publishes vitamin D3 production project EIA
Coenzyme Q10 residue application expanded to aquaculture animals
CFIA publishes 1st batch project initiation items of group standard for 2021
Guangji Pharm Mengzhou resumes production
Boxin Biotech proposes to build haematococcus pluvialis cultivation & astaxanthin extraction project
Garden Bio-Chem increases feed-grade vitamin D3 price
Xinling Chemical publicises EIA report of 5,100 t/a m-cresol upgrading project
Kunda Biotechnology suspends quotations and orders for niacinamide product
Hyperthermia and Vitamin C for Lung Cancer Treatment published in Journal of Advanced Research
Huaheng Biotech's biological enzyme-process ?-alanine derivatives project
